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The thromboxane A2 receptor (TP) has been implicated in
restenosis after vascular injury, which induces vascular smooth
muscle cell (VSMC) migration and proliferation. However, the
mechanism for this process is largely unknown. In this study, we
report that TP signaling induces VSMCmigration and prolifer-
ation through activating YAP/TAZ, two major downstream
effectors of the Hippo signaling pathway. The TP-specific
agonists [1S-[1,2(Z),3(1E,3S*),4 ]]-7-[3-[3-hydroxy-4-(4-
iodophenoxy)-1-butenyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-hep-
tenoic acid (I-BOP) and 9,11-dideoxy-9,11-methanoepoxy-
prosta-5Z,13E-dien-1-oic acid (U-46619) induce YAP/TAZ
activation in multiple cell lines, including VSMCs. YAP/TAZ
activation induced by I-BOP is blocked by knockout of the
receptor TP or knockdown of the downstream G proteins
G12/13. Moreover, Rho inhibition or actin cytoskeleton disrup-
tion prevents I-BOP-induced YAP/TAZ activation. Impor-
tantly, TP activation promotes DNA synthesis and cell migra-
tion in VSMCs in a manner dependent on YAP/TAZ. Taken
together, thromboxane A2 signaling activates YAP/TAZ to pro-
mote VSMC migration and proliferation, indicating YAP/TAZ
as potential therapeutic targets for cardiovascular diseases.
Thromboxane A2 (TxA2)4 is produced inmany cells/tissues,
particularly in platelets (1), and plays an important role in plate-
let activation and aggregation in vascular injury and atheroscle-
rosis (2). In patients with atherosclerosis or undergoing percu-
taneous transluminal coronary angioplasty (a non-surgical
procedure used to treat the narrowed coronary arteries in car-
diovascular disease), the concentration of TxA2 is significantly
increased (3–5). A similar phenomenon has also observed in
the corresponding mouse models (6–8). TxA2 and thrombox-
ane A2 receptor (TP) are believed to contribute to restenosis
after vascular injury (6, 9), which remains a challenging clinical
problem, although drug-eluting stents can reduce the risk of
restenosis (10).
TxA2 is a type of prostanoid; prostanoids are a family of
lipid mediators generated by cyclooxygenase. TxA2 is unsta-
ble, with a half-life of about 30 s, and is non-enzymatically
degraded into the biologically inactive form thromboxane B2
(TxB2) (1). TxA2 exerts its biological activity through its
cognate TP receptor, a G protein-coupled receptor (GPCR)
that couples with G12/13, Gq/11, and other trimeric G pro-
teins to regulate downstream effectors (11). TP is expressed
as two isoforms in humans: TP and TP. Besides TxA2,
prostaglandin H2, isoprostanes (such as 8-iso-prostaglandin
F2), and hydroxyeicosatetraenoic acids can also activate TP
receptors (12–14).
In addition to platelet activation, TxA2 or TP receptor is also
known to promote cell migration and proliferation of vascular
smooth muscle cells (VSMCs) (15–20), an important process
that is involved in a number of vascular diseases, such as post-
angioplasty restenosis and atherosclerosis (21). The prolifera-
tive response of VSMCs to vascular injury is markedly exagger-
ated in transgenic mice with vascular overexpression of the
humanTP receptor, which can be inhibited by theTP-specific
antagonist S18886 (6). Moreover, injury-induced vascular pro-
liferation and platelet activation are suppressed in mice genet-
ically deficient in TP receptor (6). In mouse models of athero-
sclerosis, both pharmacological antagonism and TP receptor
deletion delay lesion development (22–24). Taken together,
these previous studies demonstrate that TxA2 and TP receptor
contribute to VSMCs mediating vascular disease, although the
molecular mechanism is largely unknown.
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The Hippo signaling pathway plays a key role in the regula-
tion of organ size and tissue homeostasis (25). Core compo-
nents of the mammalian Hippo pathway include MST1/2 and
their adaptor protein SAV1, LATS1/2 and their adaptor pro-
teins MOB1A/1B, and two downstream transcriptional effec-
tors, YAP/TAZ (25). MST1/2 phosphorylate and activate
LATS1/2 kinases, which in turn phosphorylate and inhibit
YAP/TAZ. Recently, MAP4Ks have been shown to be core
components of the Hippo pathway, and they function in paral-
lel to MST1/2 to phosphorylate and activate LATS1/2 (26, 27).
Phosphorylation of YAP at Ser-127 results in cytoplasmic
sequestration because of 14-3-3 binding (28, 29). The dephos-
phorylated YAP/TAZ translocate into the nucleus and interact
with the TEAD family transcription factors to induce target
genes, such as connective tissue growth factor (CTGF) and cys-
teine-rich angiogenic inducer 61 (CYR61), thereby promoting
cell proliferation, migration, and survival (30–32). Deregula-
tion of the Hippo pathway has been observed in various human
cancers and is often correlated with a poor prognosis (33).
Upstream signals of the Hippo pathway had been elusive until
recent studies established that GPCRs relay extracellular sig-
nals to the Hippo pathway (34–38). Ligands signaling through
GPCRs coupled toG12/13, Gq/11, orGi/o activate YAP/TAZ,
whereas ligands signaling through Gs-coupled GPCRs sup-
press YAP/TAZ activity (36). Therefore, stimulation of differ-
ent GPCRs can result in either activation or inhibition of
YAP/TAZ.
Interestingly, emerging evidence shows that YAP is induced
after arterial injury and that its activation promotes smooth
muscle phenotypic switching andneointima formation (39, 40).
This led us to investigate the function of YAP/TAZ in TxA2-
and TP receptor-induced cellular signaling and VSMC migra-
tion and proliferation. In this study, we show that TP activation
increases YAP/TAZ activity in VSMCs and other cell types via
G12/13. Importantly, YAP/TAZ are essential for TP-induced
VSMC proliferation and migration, providing a plausible
mechanism for VSMC-mediated vascular diseases.
Results
Stimulation of TP Induces YAP/TAZDephosphorylation and
Nuclear Accumulation—To study TP regulation on YAP/TAZ
activity, we treated cells with the TP agonist I-BOP because the
physiological TP ligand TxA2 is extremely unstable. In serum-
starved HeLa cells that express TP, YAP was highly phosphor-
ylated. Addition of I-BOP resulted in a significant decrease in
YAP phosphorylation, as determined by immunoblotting with
a phospho-YAP antibody (Ser-127) (Fig. 1,A andB). I-BOP also
induced TAZ dephosphorylation, as indicated by the differen-
tial migration on phos-tag gels (Fig. 1B). Moreover, I-BOP-in-
ducedYAP/TAZdephosphorylationwas rapid and transient, as
the YAP/TAZdephosphorylationwas visible 15min after stim-
ulation and partially recovered 4 h after I-BOP treatment (Fig.
1B). In addition, U-46619, another TP-specific agonist, could
also induce YAP/TAZ dephosphorylation in a dose- and time-
dependent manner (supplemental Fig. 1, A and B).
Phosphorylation of YAP at Ser-127 by LATS1/2 leads to
bindingwith 14-3-3 and cytoplasmic sequestration of YAP, and
dephosphorylatedYAP accumulates in the nucleus and induces
gene expression by interacting with the transcription factors
TEAD1–4 (29, 31). Similarly, phosphorylation of TAZ at
Ser-89 by LATS1/2 also induces cytoplasmic localization (30).
As expected, I-BOP treatment caused significant nuclear accu-
mulation of YAP and TAZ (Fig. 1, C andD; supplemental Fig. 1
C) and enhanced the interaction betweenYAPandTEAD1 (Fig.
1E). A similar effect was also observed when cells were treated
with U-46619 (Fig. 1, C and D; supplemental Fig. 1C). To con-
firm the functional activation of YAP/TAZ upon TP stimula-
tion, we examined the expression of well established YAP/TAZ
target genes. The mRNA levels of CTGF and CYR61 were
significantly induced by I-BOP or U-46619 treatment
(supplemental Fig. 1,D and E). Accordingly, the CYR61 protein
level was also increased upon I-BOP stimulation (Fig. 1B).
The effect of TP activation on YAP/TAZ was consistently
observed in multiple cell lines, including MDA-MB-231,
SW480, and HEK293A (supplemental Fig. 1, F–I). Notably,
I-BOP also induces YAP/TAZ dephosphorylation in VSMCs,
such as the T/G HA-VSMC cell line and primary mouse aortic
VSMCs (MAVSMC) (Fig. 1, F–H). The effect of I-BOP onYAP/
TAZ phosphorylation was dose-dependent, and YAP/TAZ
dephosphorylation was evident when as little as 0.1 nmol/liter
I-BOP was added to primary MAVSMCs (Fig. 1H). Similarly,
the expression of YAP/TAZ target genes, such as CTGF,
CYR61, TAGLN, and EDN1, was significantly induced by
I-BOP inT/GHA-VSMCs (Fig. 1I). Based on the above data, we
conclude that stimulation of TP activates YAP/TAZ by induc-
ing their dephosphorylation and nuclear translocation.
I-BOP Acts through TP and G12/13 to Activate YAP/TAZ—
Because of the unstable property of TxA2, I-BOP and U-46619
were used to treat cells. To exclude that these chemicals have an
unexpected effect on YAP/TAZ independent of TP, we pre-
treated cells with the TP-specific antagonist SQ-29548 fol-
lowedby I-BOP treatment. As shown in Fig. 2A, I-BOP-induced
YAP/TAZdephosphorylationwas blocked by SQ-29548 inT/G
HA-VSMCs. HEK293A cells are not very sensitive to I-BOP
stimulation, likely because of the low level of TP expression.
Ectopic expression of TP receptor rendered YAP/TAZ more
sensitive to 1 nmol/liter I-BOP treatment, a concentration that
had aminor effect on YAP/TAZphosphorylation in the control
HEK293A cells (Fig. 2B). A similar phenomenon was observed
when TPwas overexpressed in U2OS cells (supplemental Fig.
2). These data indicate that I-BOP acts through both isoforms
of TP receptor to activate YAP/TAZ.
To further confirm the role of endogenous TP in YAP/TAZ
regulation, we generated TP KO cells using the CRISPR/Cas9
genome editing system. Two independent TP KO cell lines
were generated, and the TP deletion was verified by Sanger
sequencing (supplemental Fig. 3). TP knockout completely
blocked I-BOP-induced YAP/TAZ dephosphorylation and
YAP nuclear accumulation (Fig. 2, C and D). Consistently,
I-BOPwas unable to induce the expression of YAP target genes
inTPKO cells (Fig. 2E). These data show that I-BOP stimulates
TP receptor to induce YAP/TAZ activation.
TP receptor activates several trimeric G proteins, including
Gq/11 and G12/13, to initiate intracellular signaling pathways
(11). To determine which G proteins are involved in YAP/
TAZ regulation, Gq/11 or G12/13 were knocked down by
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RNAi in HEK293A cells (Fig. 2F). Knockdown of G12/13
strongly blocked YAP/TAZ dephosphorylation in response to
I-BOP, whereas knockdown of Gq/11 had little effect on
I-BOP-induced YAP/TAZ dephosphorylation (Fig. 2F). Con-
sistently, I-BOP induced YAP nuclear accumulation in control
siRNA- and Gq/11 siRNA-transfected cells but not in G12/13
FIGURE 1.Agonists of TP receptor activateYAPandTAZ.A and B, I-BOP induces YAP and TAZdephosphorylation in a dose- and time-dependentmanner inHela
cells. Cells were serum-starved for 16 h and then stimulated with I-BOP for the indicated concentration (A) or time (B). Immunoblotting was performed with the
indicated antibodies. Phos-tag gels were used for assessment of TAZ phosphorylation status. C, I-BOP and U-46619 induce YAP nuclear accumulation in HeLa cells.
HeLa cells were seeded with a density of 6 104 cells/cm2 for 12 h, starved in serum-free medium for 16 h, and stimulated with 1 nmol/liter I-BOP or 10 nmol/liter
U-46619 for 1 h. YAP subcellular localization was determined by immunofluorescence staining for endogenous YAP (green). DAPI (blue) was used for staining cell
nuclei. Representative imagesareshown.Scalebars20m.Quantificationsareshown in the rightpanel.Con, control.D, I-BOPandU-46619 induceYAP/TAZnuclear
accumulation in HeLa cells. Stimulation conditionswere same as those inC. Subcellular fractionationwas performedwithNE-PERTM nuclear and cytoplasmic extrac-
tion reagent (Thermo Fisher) according to the instructions of themanufacturer. Both fractionswere analyzed byWestern blottingwith indicated antibodies. E, I-BOP
and U-46619 enhance YAP interaction with TEAD1. Stimulation conditions were the same as in C. Cell lysates were subjected to immunoprecipitation (IP) with YAP
antibody. The coimmunoprecipitated TEAD1was detected by immunoblotting. F andG, I-BOP induces YAP/TAZdephosphorylation in a dose- and time-dependent
manner in T/G HA-VSMCs. Cells were serum-starved for 16 h and then stimulated with I-BOP for the indicated concentration (F) or time (G). Immunoblotting was
performedwith the indicatedantibodies. Phos-taggelswereused forassessmentofYAP/TAZphosphorylationstatus.H, I-BOP inducesYap/Tazdephosphorylation in
a dose-dependent manner in primary MAVSMCs. Cells were serum-starved for 16 h and then stimulated with I-BOP for the concentration as indicated. FBS was
includedasapositivecontrol. Immunoblottingwasperformedwith the indicatedantibodies.Phos-taggelswereused forassessmentofYapandTazphosphorylation
status. I, I-BOP induces expression of YAP target genes. T/GHA-VSMCswere treatedwith 1 nmol/liter I-BOP for 2 h after serum-starved for 16 h.mRNA levels of CTGF,
CYR61, TAGLN, and EDN1weremeasured by quantitative PCR.
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FIGURE 2. TP agonist activates YAP/TAZ via TP receptor andG12/13. A, the TP antagonist SQ-29548 blocks YAP/TAZ dephosphorylation induced by I-BOP.
Serum-starved T/GHA-VSMCswere pretreatedwith the TP-specific antagonist SQ-29548 (1mol/liter) for 3 h and then stimulatedwith I-BOP (1 nmol/liter) for
1h.Cell lysateswere subjected to immunoblottingwith the indicatedantibodies.B, ectopic expressionof TP receptor rendersHEK293Acells sensitive to I-BOP
treatment. HEK293A cells were transiently transfectedwith the indicated plasmids and stimulatedwith different concentrations of I-BOP for 1 h. Immunoblot-
ting was performed with the indicated antibodies. C, knockout of TP blocks I-BOP-induced YAP/TAZ dephosphorylation. Wild-type or TP KO HEK293A cells,
which were verified by genomic DNA sequencing (supplemental Fig. 3), were seeded with a density of 8 104 cells/cm2 for 24 h and then treated with 10
nmol/liter I-BOP for 1 h. Immunoblotting was performed with the indicated antibodies. Con, control. D, TP KO abolishes I-BOP-induced YAP nuclear translo-
cation. Stimulation conditions were the same as in C. YAP localization was determined by immunofluorescence. Scale bars 30 m. E, TP KO blocks I-BOP-
induced target gene expression. Wild-type or TP KO HEK293A cells were treated with 10 nmol/liter I-BOP for 2 h. mRNA levels of CTGF and CYR61 were
measuredbyquantitative PCR. F, I-BOPactivates YAP/TAZviaG12/13. HEK293Acellswere transfectedwith the indicated siRNAs. Amixtureof two independent
oligonucleotides was used for one gene. Two days after transfection, cells were treated with 10 nmol/liter I-BOP for 1 h. cells were lysed and subjected to
immunoblottingwith the indicated antibodies.G, knockdownofG12/13 blocks I-BOP-induced YAPnuclear localization. Stimulation conditionswere similar as
in F. Immunofluorescence staining for endogenous YAP (green), F-actin (red), and DNA (blue) is presented. Scale bars 20 m.
YAP/TAZMediates Thromboxane A2 Signaling
18950 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 36•SEPTEMBER 2, 2016
siRNA-transfected cells (Fig. 2G, supplemental Fig. 4). Taken
together, we conclude that TP signals through G12/13 to
induce YAP/TAZ dephosphorylation and activation.
I-BOP Modulates YAP/TAZ Dephosphorylation via Rho
GTPase and the Actin Cytoskeleton—Rho GTPase is a known
downstream signaling module of G12/13, which directly inter-
acts and activates the Rho guanine nucleotide exchange factor.
We therefore tested the role of Rho GTPase in I-BOP-induced
YAP/TAZ dephosphorylation. Expression of Rho GDP dissoci-
ation inhibitor, which binds to Rho GTPase and inhibits
GTPase cycling, suppressed I-BOP-inducedYAP/TAZdephos-
phorylation (Fig. 3A). Likewise, botulinum toxin C3, a specific
inhibitor of Rho GTPase, strongly blocked YAP/TAZ dephos-
phorylation in response to I-BOP or U-46619 treatment (Fig.
3B; supplemental Fig. 5, A and B). Consistently, C3 treatment
blocked I-BOP- or U-46619-induced YAP nuclear transloca-
tion (Fig. 3C, supplemental Fig. 5C). These data indicate that
Rho GTPase is required for TP to activate YAP/TAZ.
The major function of Rho GTPase is to modulate the actin
cytoskeleton, particularly stress fiber formation. Recently stud-
ies have shown that the actin cytoskeleton plays an important
role in the Hippo pathway (41–45). We therefore tested
whether cytoskeletal reorganization contributes to YAP/TAZ
activation by TP agonists. Latrunculin B, an F-actin-disrupting
reagent, blocked I-BOP- or U-46619-induced YAP/TAZ
dephosphorylation (Fig. 3D, supplemental Fig. 5D). Consistent
with changes in YAPphosphorylation, Latrunculin B treatment
also preventedYAPnuclear accumulation in response to I-BOP
orU-46619 (Fig. 3E, supplemental Fig. 5E).Moreover, I-BOP or
U-46619 induced actin stress fiber and YAP nuclear transloca-
tion (Figs. 2G and 3, C and E; supplemental Fig. 5, C and E).
Knockdown of G12/13 or treatment with C3 or Latrunculin B
disrupted F-actin formation and YAP nuclear accumulation
(Figs. 2G and 3, C and E; supplemental Fig. 5, C and E). These
results indicate that TP acts through Rho GTPase and the actin
cytoskeleton to affect YAP/TAZ phosphorylation.
I-BOP Inhibits LATS—LATS1/2 are the kinases directly
responsible for YAP/TAZ phosphorylation. The phosphoryla-
tion of the activation loop (Ser-909/Ser-872 for LATS1/2) and
hydrophobic motif (Thr-1079/Thr-1041 for LATS1/2) corre-
lates with LATS1/2 kinase activity (46). To test whether
LATS1/2 kinases are involved in I-BOP-induced YAP/TAZ
activation, we measured LATS1 kinase activity in vitro. LATS1
was potently inhibited by I-BOP treatment, as determined by its
autophosphorylation at Ser-909 and in vitro phosphorylation of
the purified GST-YAP (Fig. 4A). Consistent with the results
described in Fig. 3, B and C, inhibition of Rho GTPase by C3
blocked the inhibitory effect of I-BOP on LATS1 kinase activity
(Fig. 4A), indicating that Rho GTPase activation is required for
I-BOP-induced LATS1 inhibition. To further determine the
role of LATS1/2 in YAP regulation by I-BOP, we used LATS1/2
double knockout (LATS1/2 dKO)HEK293A cells. As expected,
FIGURE 3. I-BOP activates YAP/TAZ through Rho and cytoskeletons. A, I-BOP-induced YAP/TAZ dephosphorylation is blocked by Rho-GDP dissociation
inhibitor expression. HEK293A cells were transiently transfected with the indicated plasmids and incubated with 10 nmol/liter I-BOP for 1 h. Immunoblotting
was performed with the indicated antibodies. B, inactivation of Rho by C3 prevents YAP/TAZ dephosphorylation. Serum-starved T/G HA-VSMCs were pre-
treated with C3 (4 g/ml) for 3 h and then stimulated with I-BOP (1 nmol/liter) for 1 h. The cell lysates were subjected to immunoblotting analysis with the
indicated antibodies. C, inactivation of Rho by C3 prevents YAP nuclear accumulation. Serum-starved HEK293A cells were pretreatedwith C3 (2g/ml) for 3 h
and then stimulated with I-BOP (10 nmol/liter) for 1 h. After fixation, immunofluorescence staining was performed for endogenous YAP (green) and F-actin
(red). DAPI (blue) was used for staining cell nuclei. Scale bars  20 m. Con, control. D, disruption of the actin cytoskeleton blocks I-BOP-induced YAP/TAZ
dephosphorylation. Serum-starved T/G HA-VSMCswere pretreatedwith Latrunculin B (LatB, 1g/ml) for 10min and then stimulatedwith I-BOP (1 nmol/liter)
for the indicated time. The cell lysates were subjected to immunoblotting analysis with the indicated antibodies. E, disruption of the actin cytoskeleton blocks
I-BOP-induced YAP nuclear localization. HEK293A cells were pretreatedwith Latrunculin B (1g/ml) for 10min and then stimulatedwith I-BOP (10 nmol/liter)
for 1 h. The immunofluorescence staining is similar as in C. Scale bars 20 m.
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I-BOP could not affect YAP/TAZ phosphorylation in LATS1/
2-dKO cells (supplemental Fig. 6), suggesting that LATS1/2 are
required for I-BOP-induced YAP/TAZ dephosphorylation.
MST1/2 and MAP4Ks are responsible for LATS kinase acti-
vation in response to upstream signals (26, 27, 46). To test
whether MST1/2 or MAP4Ks are involved in I-BOP-induced
YAP/TAZ dephosphorylation, we usedMST1/2 double knock-
out (MST1/2 dKO) and combined deletion of MST1/2 and
MAP4K1/2/3/4/5/6/7 (MM-9KO) HEK293A cells (supple-
mental Fig. 7). I-BOP-induced YAP/TAZ dephosphorylation
was largely unaffected inMST1/2 dKO cells (Fig. 4B). However,
I-BOP had no effect on YAP/TAZ phosphorylation in
MM-9KO cells (Fig. 4C). In addition, re-expression ofMST2 or
MAP4K2 could restore the effect of I-BOP on YAP phosphor-
ylation in MM-9KO cells (Fig. 4D). I-BOP-induced LATS inhi-
bition was abolished in MM-9KO cells, as shown by in vitro
kinase assay (Fig. 4E). Taken together, these results suggest that
MAP4Ks play a major role in I-BOP-induced YAP/TAZ
dephosphorylation, although both MST1/2 and MAP4Ks are
involved.
YAP/TAZAre Required for TP to Stimulate VSMCDNA Syn-
thesis and Cell Migration—TP has been shown to promote
neointima formation, which is caused by VSMCmigration and
proliferation (6, 9, 47). Because YAP/TAZ activity is signifi-
cantly activated upon TP stimulation in VSMCs, we investi-
gated whether YAP/TAZ activation is involved in the prolifer-
ation and migration of VSMCs. YAP/TAZ were knocked down
in T/G HA-VSMCs by inducible shRNA and siRNA, respec-
tively. The knockdown efficiency was confirmed by immuno-
blotting of protein levels (Fig. 5A). Knockdown of YAP/TAZ
significantly suppressed the mRNA induction of CTGF and
CYR61 in response to I-BOP (Fig. 5B). I-BOP strongly induced
cell migration in control cells, whereas this effect was signifi-
cantly suppressed in YAP/TAZ double knockdown cells (Fig. 5,
C and D). In addition, I-BOP-induced VSMC DNA synthesis
was also suppressed by YAP/TAZ double knockdown, as deter-
FIGURE4. I-BOP inhibits LATS.A, I-BOP inhibits theactivation loopphosphorylationof LATS1 inaRho-dependentmanner.HEK293Acellswerepretreatedwith
C3 (2g/ml) for 3 h and then stimulatedwith I-BOP (10 nmol/liter) for 1 h. The presence of FBS is indicated. Cell lysateswere subjected to immunoprecipitation
(IP) with control IgG or LATS1 antibody. The immunoprecipitated LATS1 was measured for the in vitro kinase assays using GST-YAP as a substrate. The
phosphorylation of LATS1 and GST-YAP was detected by immunoblotting with the indicated antibodies. B, MST1/2 are not essential for I-BOP-induced
YAP/TAZdephosphorylation.Wild-typeorMST1/2dKOHEK293Acellswere treatedwith I-BOP (10nmol/liter) for the indicated timepoints. Thecell lysateswere
subjected to immunoblotting with the indicated antibodies. C, both MST1/2 and MAP4Ks are involved in I-BOP-induced YAP/TAZ dephosphorylation. Wild-
type or MM-9KO HEK293A cells, which were verified by genomic DNA sequencing (supplemental Fig. 7), were treated with I-BOP (10 nmol/liter) for the
indicated time. The cell lysateswere subjected to immunoblotting as indicated. D, re-expression ofMST1/2 orMAP4K2 inMM-9KOcells restores I-BOP-induced
YAP/TAZ dephosphorylation. Wild-type orMM-9KOHEK293A cells were transfectedwith the indicated plasmids and treatedwith I-BOP (10 nmol/liter) for 1 h.
The cell lysates were subjected to immunoblotting as indicated. E, MST1/2 andMAP4Ks are required for I-BOP to induce LATS inhibition.Wild-type orMM-9KO
HEK293A cells were transfected with the indicated plasmids and treated with I-BOP (10 nmol/liter) for 1 h. The Cell lysates were subjected to immunoprecipi-
tation with FLAG beads. The immunoprecipitated FLAG-LATS1 was measured for in vitro kinase assays using GST-YAP as a substrate. The phosphorylation of
LATS1 and GST-YAP was detected by immunoblotting with the indicated antibodies.
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FIGURE 5. YAP/TAZmediate the effect of TP in gene induction, DNA synthesis, and cell migration in VSMCs. A, knockdown of YAP/TAZ by shRNAs and
siRNAs in T/G HA-VSMCs. Cells were transfected with the indicated siRNAs. 48 h after transfection and doxycycline (Dox) induction, cells were lysed and
subjected to immunoblottingwith the indicated antibodies. B, YAP/TAZ are required for I-BOP-inducedgene expression. T/GHA-VSMCswere transfectedwith
the indicated siRNAsand serum-starved for 24h in thepresenceofdoxycycline. After treatmentwith I-BOP (1nmol/liter) for 1h,mRNA levels ofCTGFandCYR61
were measured by real-time PCR. The numbers next to each treatment conditions will be used to label C–E. C, YAP/TAZ are required for I-BOP-induced cell
migration. The treatment conditions for each panel are the same as in B. After stimulation with I-BOP (1 nmol/liter) for 4 h, cell migration was performed by
transwell cellmigration assay. Representative images are shown.Con, control.D, quantification result of thedata inC. *,p0.05. Statistical analysis is described
under “Experimental Procedures.” E, YAP/TAZ are required for I-BOP-induced DNA synthesis. T/G HA-VSMCswere treated as indicated in B and then subjected
to an EdU incorporation assay as described under “Experimental Procedures.” About 600–1000 randomly selected cells are quantified and shown. *, p 0.05.
F, Yap/Taz knockdownby siRNAs in primaryMAVSMCs. Cellswere transfectedwith the indicated siRNAs. After 48-h transfection, cellswere lysed and subjected
to immunoblotting with the indicated antibodies. G, Yap/Taz are required for primary MAVSMCs migration induced by I-BOP. Primary MAVSMCs were
transfectedwith the indicated siRNAs and serum-starved for 20 h. After stimulationwith I-BOP (1 nmol/liter) for 4 h, cellmigrationwas determinedby transwell
cell migration assay. Representative images are shown. H, quantification result of the data in G. *, p 0.05.
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minedbyEdU incorporation (Fig. 5E, supplemental Fig. 8A). To
further support the important role of the TP-YAP/TAZ axis in
VSMCs, we isolated and analyzed primaryMAVSMCs. Similar
Yap/Taz knockdown experiments were performed in primary
MAVSMCs. Consistently, knockdown of Yap/Taz in primary
MAVSMCs also inhibited cell migration induced by I-BOP
(Fig. 5, F–H). In addition, we observed that YAP/TAZ knock-
down suppressed I-BOP-induced gene expression and cell
migration in HeLa cells (supplemental Fig. 8, B–D). Taken
together, these results demonstrate that YAP/TAZ play an
important role in TP-mediated gene induction, cell prolifera-
tion, and migration in VSMCs.
Discussion
TxA2 is involved in multiple physiological and pathophysio-
logical processes, including thrombosis, asthma, myocardial
infarction, inflammation, atherosclerosis, and the response to
vascular injury (11). TxA2 exerts its biological activity via its
cognate TP receptor. In this study, we demonstrate that the
Hippo pathway is a crucial downstream signalingmodule of TP
receptor, a classical GPCR. TP agonists significantly activate
YAP/TAZ in multiple cells lines, including VSMCs. Our data
also demonstrate that activation of TP couples to G12/13 to
trigger the activation of Rho GTPase, which modulates the
actin cytoskeleton to inhibit LATS1/2 kinase activity, resulting
in YAP/TAZ dephosphorylation and activation (Fig. 6). In this
signaling cascade, both MST1/2 and MAP4Ks, the major
kinases for LATS1/2, are involved in Hippo pathway regulation
by TP. Our studies indicate a functional role of the Hippo path-
way and YAP/TAZ in mediating the physiological and patho-
logical functions of thromboxane and its receptor TP.
In addition to TxA2, there are four other major prostaglan-
dins generated from arachidonic acid in vivo, including prosta-
glandin D2, prostaglandin E2, prostaglandin F2, and prostacy-
clin (48). They all exert their effects via corresponding GPCRs.
It is interesting to speculate that YAP/TAZ may play a similar
role in physiological and disease processes that are regulated by
prostaglandins, such as inflammation, atherosclerosis, and can-
cer (49). For instance, the prostacyclin receptor couples to Gs
and stimulates cAMP production and PKA activation (50). Pre-
viously we reported that cAMP acts through PKA to stimulate
LATS kinases and inhibit YAP (51). Given that TxA2 and pros-
tacyclin are antagonistic in their actions in cardiovascular dis-
ease (6), it will be interesting to determinewhether prostacyclin
inhibits YAP/TAZ, thereby antagonizing the effect of TxA2,
which activates YAP/TAZ, as shown in this report, in cardio-
vascular disease.
Isoprostanes are prostaglandin-like compounds formed from
the free radical-catalyzed peroxidation of unsaturated fatty
acids, such as arachidonic acid, that are recognized not only as
reliable markers of oxidative stress but also as important medi-
ators of various diseases (52). Increased formation of isopros-
tanes has been observed in diseases that are linked to oxidative
stress, such as cardiovascular disease and cancer (52). As men-
tioned above, isoprostanes act, at least partially, via TP to exert
their physiological effects. So onemay speculate that YAP/TAZ
also play a role in isoprostane-mediated pathophysiological
effects. Indeed,we observed that 8-iso-prostaglandin F2, a type
of isoprostanes, could induce YAP/TAZ dephosphorylation in
VSMCs.5 Future studies are needed to delineate the involve-
ment and potential role of YAP/TAZ in isoprostane-induced
physiological processes.
Our study shows that YAP/TAZ are required for TP-stimu-
latedVSMCDNAsynthesis and cellmigration. The connection
between TP receptor and the Hippo pathway in vascular
smooth muscle cells has important physiological implications.
During vascular injury, activated platelets or other cells pro-
duce TxA2, which in turn promotes platelet activation and
aggregation (4, 53). Besides TxA2, isoprostanes may also act
through the TP receptor on the surface of smooth muscle cells
and initiate the migration from media to intima via YAP/TAZ
activation. Previous studies have reported that YAP is activated
in VSMCs of the neointima (39). We propose that thrombox-
ane acts through TP to induce YAP/TAZ activation to promote
normal physiological wound healing in response to vascular
injury. However, too much YAP/TAZ activation by TP under
pathological conditions may lead to VSMC overgrowth,
thereby contributing to neointima formation and restenosis.
Notably, CTGF andCYR61 are strongly induced uponTP stim-
ulation in a manner dependent on YAP/TAZ (Figs. 2E and 5B).
Both CTGF and CYR61 have been shown to promote athero-
sclerotic lesion development and neointimal hyperplasia (54–
5 X. Feng, P. Liu, X. Zhou, M. T. Li, F. L. Li, Z. Wang, Z. Meng, Y. P. Sun, Y. Yu, Y.
Xiong, H. X. Yuan, and K. L. Guan, unpublished data.
FIGURE 6.Aproposedmodel for thromboxane A2 receptor in the regula-
tion of YAP/TAZ activities.
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56); therefore, uncontrolled expression of these proteins may
contribute to pathology associatedwithTPhyperactivation.No
TP antagonist has been used in clinics because of efficacy and
toxicity issues (2). Ourwork reveals new insights into the role of
the Hippo pathway and YAP/TAZ in thromboxane pathophys-
iology and suggests YAP/TAZ as potential therapeutic targets
for vascular diseases. Actually, a small molecule, verteporfin
(trade name Visudyne), a clinical drug for neovascular macular
degeneration (57), has been shown to efficiently inhibit
TEAD-YAP interaction and suppress YAP-induced liver over-
growth (58). The data in this report suggest that YAP/TAZ
inhibitors could be a potential treatment for vascular diseases
caused by VSMC overgrowth.
Experimental Procedures
Plasmids—The plasmids pCMV-HA-YAP2, FLAG-LATS1,
FLAG-MST2, and FLAG-MAP4K2 and GFP-GDP dissociation
inhibitor were described before (26, 51, 59). TP/were ampli-
fied from cDNA and then subcloned into pRK7-N-FLAG and
pQCXIH vectors with the restriction enzymes BamHI/EcoRI.
Antibodies—Antibodies for YAP (4912), phospho-YAP (Ser-
127, 4911), MST1 (3682), MST2 (3952), CYR61 (11952), phos-
pho-MST1 (Thr-183)/MST2 (Thr-180, 3681), phospho-
LATS1 (Ser-909, 9157), and phospho-LATS1 (Thr-1079, 8654)
were purchased from Cell Signaling Technology. The LATS1
(A300-477A) andYAP (A302-308A) antibodies used for immu-
noprecipitation and LATS2 (A300-479A) antibody were from
Bethyl Laboratories. TAZ (HPA007415) and Vinculin (V9264)
antibodies were obtained from Sigma-Aldrich. Anti-TEAD1
(610922) was purchased from BD Transduction Laboratories.
Antibodies for Gq/11 (Cys-19, sc-392) and G12 (Ser-20,
sc-409) and the HA-probe antibody (sc-7392) were from Santa
Cruz Biotechnology. The tubulin antibody (581P) was pur-
chased from NeoMarkers, and anti--actin (A00702), Lamin
A/C (A01455), and anti-FLAG antibodies were purchased from
GeneScript. The GFP tag (7G9, M20004) was from Abmart.
The anti-G protein 13 antibody (EPR5436, ab128900) was
obtained from Abcam.
Chemicals—U-46619 (9,11-dideoxy-9,11-methanoepoxy-
prosta-5Z,13E-dien-1-oic acid) and SQ-29548 ([1S-
[1,2(Z),3,4]]-7-[3-[[2-[(phenylamino)carbonyl]hydrazino]-
methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid) were
purchased from Santa Cruz Biotechnology. I-BOP ([1S-
[1,2(Z),3(1E,3S*),4 ]]-7-[3-[3-hydroxy-4-(4-iodophenoxy)-
1-butenyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid) was
purchased from Cayman Chemical. Latrunculin B and tetra-
methylrhodamine B isothiocyanate-conjugated Phalloidin
were purchased from Sigma-Aldrich. C3 was from Cytoskele-
ton Inc. Phos-tag was purchased from Wako chemicals. DAPI
was purchased from Invitrogen.
Generation of Knockout Cells Using CRISPR/Cas9 Genome
Editing—To generate TP knockout HEK293A cells, the follow-
ing guide sequence targeting the human TBXA2R gene was
used: 5-GCTGGTGACCGGTACCATCG-3. The detail pro-
tocol is described elsewhere (26). Two independent clones with
TBXA2R gene deletion were used for experiments. MST1/2
dKO and LATS1/2 dKO HEK293A cells were described previ-
ously (26). MM-9KO HEK293A cells were generated based on
MM-8KO cells (26). The following guide sequence targeting
the human MAP4K5 gene was used: 5-CACCTAC-
GGGGACGTCTATA-3. Gene deletion was verified by Sanger
sequencing of genomic DNA (supplemental Figs. S3 and S7).
Cell Culture—HEK239A and HeLa cells were cultured in
DMEM (Invitrogen). U2OS cells were cultured in RPMI 1640
medium (Invitrogen). All of the above cells were supplemented
with 10% FBS (Gibco) and 50 g/ml penicillin/streptomycin.
T/G HA-VSMCs were cultured in DMEM/F12 medium (Invit-
rogen) and supplemented with 0.05 mg/ml ascorbic acid, 0.01
mg/ml insulin, 0.01 mg/ml transferrin, 10 ng/ml sodium sele-
nite, 0.03 mg/ml endothelial cell growth supplement, and 50
g/ml penicillin/streptomycin. Mouse primary aortic VSMCs
were isolated from 4- to 8-week-old C57BL/6malemice using a
standard protocol (60) and incubated in DMEM supplemented
with 20% FBS and 50 g/ml penicillin/streptomycin. Cells at
passages 3–5 were used. For serum starvation, cells were incu-
bated in DMEM or DMEM/F12 without serum. All cell lines
were maintained at 37 °C with 5% CO2.
Transfection and Lentiviral and Retroviral Infection—Cells
were transfected with plasmid DNA using PEI. To generate
U2OS cells stably expressing TP/, retroviruses carrying
pQCXIH empty vector or pQCXIH-TP/ were produced in
HEK293T cells using vesicular stomatitis virus G and GAG as
packaging plasmids. The virus supernatantwas filtered through
a 0.45-m filter and used to infect targeting cells in the pres-
ence of 8 g/ml Polybrene. Stable cell pools were selected with
50 g/ml hygromycin B (Amresco) for 5 days. For tetracycline-
inducible shRNA expression, a lentivirus containing shRNAs in
the pTRIPZ vector was made in HEK293T cells using pMD2.g
and psPAX2 as packaging plasmids. Virus infection was per-
formed as described above except for selection with 1 g/ml
puromycin (Amresco) for 5 days. Expression of shRNA was
induced by adding 1 g/ml doxycycline for 48 h. The shRNA
sequences against YAPwere as follows: YAP#1, TTCTTTATCT-
AGCTTGGTGGC; YAP#2, TGGTCAGAGATACTTCTTAAA.
RNA Interference—siRNAs targetingGNAQ,GNA11,GNA12,
GNA13, YAP1/Yap1, and WWTR1/Wwtr1 were from Gene-
pharma and were delivered into cells using RNAiMAX (Invitro-
gen) according to the instructions of the manufacturer. The
sequencesof all siRNAsused in this studywereas follows: siGNAQ
#1, GACACCGAGAATATCCGCTTT; siGNAQ #2, CTAT-
GATAGACGACGAGAATA; siGNA11 #1, GCTCAAGATC-
CTCTACAAGTA; siGNA11#2, GCTCAACCTCAAGGAGTA-
CAA; siGNA12#1, GCGACACCATCTTCGACAA; siGNA12#2,
GGATGTTCCTGATGGCCTT; siGNA13#1, GCTCGAGAG-
AAGCTTCATA; siGNA13#2, CCTGCTATAAGAGCATTAT;
siYAP1#1, CCCAGTTAAATGTTCACCAAT; siYAP1#2, CAG-
GTGATACTATCAACCAAA; siTAZ#1, CAGCCAAAT-
CTCGTGATGAAT; siTAZ#2, GCGATGAATCAGCCTCT-
GAAT; siYap1#1,GAAGCGCTGAGTTCCGAAATC; siYap1#2,
TGAGAACAATGACAACCAATA; siTaz#1, CAGCCGAAT-
CTCGCAATGAAT; and siTaz#2, CCATGAGCACAGATAT-
GAGAT.
RNAExtraction andReal-time PCR—Cells werewashedwith
cold PBS, and total RNA was isolated using TRIzol reagent fol-
lowing the instructions of the manufacturer (Invitrogen). 1 g
of RNAwas reverse-transcribed to cDNAwith oligo(dT) prim-
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ers (Transgene). cDNA was then diluted and subjected to real-
time PCR with gene-specific primers using SYBR Premix Ex
Taq (TaKaRa) and the 7500 real-time PCR system (Applied
Biosystems). The primer pairs used in this study were as
follows: Actin, GCCGACAGGATGCAGAAGGAGATCA/AA-
GCATTTGCGGTGGACGATGGA; CTGF, CCAATGACAAC-
GCCTCCTG/TGGTGCAGCCAGAAAGCTC; CYR61, AGCC-
TCGCATCCTATACAACC/TTCTTTCACAAGGCGGCACTC;
EDN1, TGTGTCTACTTCTGCCACCT/CCCTGAGTTCTTT-
TCCTGCTT; ANKRD1, CACTTCTAGCCCACCCTGTGA/C-
CACAGGTTCCGTAATGATTT; TAGLN, CCCGAGAACCC-
ACCCTCCA/AAAGCCATCAGGGTCCTCTGC; TP, CCT-
TCTGGTCTTCATCGCCC/CTGGAGGGACAGCGACCT;
and TP, ACCCGGCCCAGACGGAGT/GGACAGAGCC-
TTCCCTGTTGG.
Immunoprecipitation—Cells were lysed using lysis buffer (50
mM Tris (pH 7.5), 150 mM NaCl, 0.5% Nonidet P-40, 50 mM
NaF, 1.5 mM Na3VO4, 1 mM PMSF, and protease inhibitors).
Cell lysates were centrifuged at 12,000  g for 15 min at 4 °C.
The supernatants were incubated with YAP antibody (Bethyl
Laboratories) for 2 h, followed by protein A-agarose bead incu-
bation for 1 h. Immunoprecipitates were washed three times
with lysis buffer, and proteins were boiled with SDS-PAGE
sample buffer.
Immunoblotting—Cells were lysed in SDS sample buffer and
denatured by heating on 99 °C for 10min. Immunoblotting was
performed in 8% or 10% BisTris polyacrylamide gel according
to the standard protocol. The phos-tag reagents were pur-
chased from Wako Chemicals, and gels containing phos-tag
were prepared following the instructions of the manufacturer.
YAP and TAZ proteins can be separated into multiple bands in
phos-tag gels depending on differential phosphorylation levels,
with phosphorylated YAP/TAZ migrating more slowly.
Immunofluorescence Staining—Cells seeded in 6-well plates
were treated as indicated in specific experiments. After treat-
ment, they were fixed immediately with 4% paraformaldehyde
for 20 min and then permeabilized with 0.5% Triton X-100 in
PBS for 5 min on ice. After blocking in 5% BSA for 30 min, cells
were incubated with primary antibodies overnight at 4 °C. Cells
were washed with PBS three times for 5 min, and Alexa Fluor
488-conjugated secondary antibodies were added for 1 h at
room temperature. Tetramethylrhodamine B isothiocyanate-
conjugated Phalloidin was used to stain actin filaments, and
DAPI was used for cell nuclei. Photos were taken by an Olym-
pus IX81 inverted research microscope with appropriate fluo-
rescence filters.
Cell Fractionation—HeLa cells were seeded with a density of
6  104 cells/cm2 for 12 h, starved in serum-free medium for
16 h, and stimulated with 1 nmol/liter I-BOP or 10 nmol/liter
U-46619 for 1 h. Subcellular fractionation was performed
with NE-PERTM nuclear and cytoplasmic extraction reagent
(Thermo Fisher) according to the instructions of the manufac-
turer. Both fractions were analyzed by Western blotting.
InVitro KinaseAssay—LATS1 kinase assaywas performed as
described before (38). Briefly, LATS1 was immunoprecipitated
from cells and subjected to an in vitro kinase assay using GST-
YAP as a substrate. The phosphorylation levels of GST-YAP at
Ser-127 were determined by immunoblotting using phospho-
YAP (Ser-127) antibody.
Transwell Migration Assay—Cell migration assays were per-
formed using BD Falcon Cell culture inserts for 24-well plates
with 8.0-mpore filters. Cells were serum-starved for 20 h and
then stimulated with I-BOP or vehicle for 4 h. Cells (6  104
T/G HA-VSMCs, 5 104 primary aortic VSMCs, and 2 105
HeLa cells) were seeded into the upper chamber of the insert for
each well in DMEM/F-12 without other supplements, and the
lower chamber of the plate was filled with DMEM/F-12 supple-
mented with 10% FBS. After 6 h for T/G HA-VSMC (3 h for
primary MAVSMC and 24 h for HeLa), cells were fixed using
4% paraformaldehyde and stained with 0.05% crystal violet.
Cells in the upper chamber were removed by scrubbing with a
cotton swab, and cells migrated through the filter were photo-
graphed and quantified.
EdU Incorporation Assay—T/G HA-VSMCs grown on
24-well plates were serum-starved for 24 h. I-BOP (1 nmol/
liter) was added every 8 h for 3 times. 10 mol/liter EdU
(5-ethynyl-2-deoxyuridine) was added to the culture
medium for 4 h. After labeling, cells were fixed with 4% para-
formaldehyde for 20 min, followed by permeabilization with
0.5% Triton X-100 in PBS for 20 min at room temperature.
Cells were rinsed once with PBS and incubated with mixture
reaction buffer (100 mmol/liter sodium ascorbate, 4.8 mol/
liter Alexa Fluor 488 azide, and 4 mmol/liter CuSO4) for 30
min at room temperature. After staining, cells were washed
three times with 0.5% Triton X-100 in PBS, and DAPI was
used for cell nuclei. Photos were taken by an Olympus IX81
inverted research microscope.
Statistical Analysis—All data are expressed as mean  S.E.
Two-group comparison was analyzed by Student’s t test. p 
0.05 was considered significant.
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